Squarepoint’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.13M | Sell |
13,963
-21,494
| -61% | -$3.29M | ﹤0.01% | 2134 |
|
|
2025
Q4 | $4.89M | Buy |
35,457
+26,616
| +301% | +$3.49M | 0.01% | 1476 |
|
|
2025
Q3 | $1.13M | Sell |
8,841
-18,692
| -68% | -$2.28M | ﹤0.01% | 2585 |
|
|
2025
Q2 | $3.33M | Buy |
27,533
+12,582
| +84% | +$1.42M | ﹤0.01% | 1733 |
|
|
2025
Q1 | $1.67M | Buy |
14,951
+11,205
| +299% | +$1.19M | ﹤0.01% | 2243 |
|
|
2024
Q4 | $365K | Buy |
+3,746
| New | +$399K | ﹤0.01% | 4009 |
|
|
2024
Q2 | – | Sell |
-62,752
| Closed | -$6.3M | – | 4472 |
|
|
2024
Q1 | $6.07M | Buy |
+62,752
| New | +$6.43M | 0.01% | 1323 |
|
|
2023
Q4 | – | Sell |
-35,957
| Closed | -$3.47M | – | 4337 |
|
|
2023
Q3 | $3.66M | Sell |
35,957
-8,107
| -18% | -$823K | 0.01% | 1380 |
|
|
2023
Q2 | $4.45M | Buy |
44,064
+26,862
| +156% | +$2.69M | 0.01% | 1138 |
|
|
2023
Q1 | $1.58M | Buy |
17,202
+2,701
| +19% | +$236K | 0.01% | 1578 |
|
|
2022
Q4 | $1.32M | Buy |
14,501
+3,668
| +34% | +$309K | 0.01% | 1630 |
|
|
2022
Q3 | $823K | Buy |
10,833
+3,521
| +48% | +$292K | ﹤0.01% | 1891 |
|
|
2022
Q2 | $618K | Sell |
7,312
-7,095
| -49% | -$622K | ﹤0.01% | 1896 |
|
|
2022
Q1 | $1.26M | Sell |
14,407
-27,101
| -65% | -$2.35M | 0.01% | 1446 |
|
|
2021
Q4 | $3.63M | Buy |
+41,508
| New | +$3.45M | 0.01% | 937 |
|
|
2021
Q3 | – | Sell |
-70,836
| Closed | -$6.46M | – | 3265 |
|
|
2021
Q2 | $6.46M | Buy |
70,836
+46,269
| +188% | +$4.12M | 0.02% | 628 |
|
|
2021
Q1 | $2.1M | Buy |
24,567
+10,727
| +78% | +$963K | 0.01% | 1038 |
|
|
2020
Q4 | $1.31M | Sell |
13,840
-2,874
| -17% | -$251K | 0.01% | 1168 |
|
|
2020
Q3 | $1.45M | Buy |
+16,714
| New | +$1.45M | 0.02% | 802 |
|
|
2020
Q1 | – | Sell |
-17,353
| Closed | -$1.64M | – | 2321 |
|
|
2019
Q4 | $1.64M | Buy |
+17,353
| New | +$1.56M | 0.01% | 1026 |
|
|
2019
Q3 | – | Sell |
-30,468
| Closed | -$2.78M | – | 2583 |
|
|
2019
Q2 | $2.78M | Buy |
+30,468
| New | +$2.58M | 0.03% | 672 |
|
|
2019
Q1 | – | Sell |
-4,258
| Closed | -$327K | – | 2356 |
|
|
2018
Q4 | $327K | Buy |
+4,258
| New | +$331K | ﹤0.01% | 1467 |
|
|
2018
Q1 | – | Sell |
-7,126
| Closed | -$536K | – | 1999 |
|
|
2017
Q4 | $536K | Buy |
+7,126
| New | +$538K | 0.01% | 1169 |
|
|
2017
Q1 | – | Sell |
-7,084
| Closed | -$462K | – | 1800 |
|
|
2016
Q4 | $462K | Buy |
+7,084
| New | +$460K | 0.02% | 882 |
|
|
2016
Q3 | – | Sell |
-3,398
| Closed | -$251K | – | 1181 |
|
|
2016
Q2 | $251K | Buy |
+3,398
| New | +$235K | 0.02% | 814 |
|
Other funds holding NVS
Squarepoint's NVS Position: Q1 2026 in Review
Squarepoint reduced its Novartis (NVS) stake by 61% in Q1 2026, selling an estimated $3.29M and leaving 13,963 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2134.
Squarepoint first reported a position in NVS in Q2 2016 and has held it in 25 quarters since. The position peaked at $6.46M in Q2 2021. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Squarepoint held 13,963 shares of Novartis worth $2.13M as of Q1 2026.
- Squarepoint sold 21,494 Novartis shares in Q1 2026, an estimated $3.29M.
- Novartis made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2134 holding.
- Squarepoint first reported a position in Novartis in Q2 2016 and has held it in 25 quarters since.
- Squarepoint's Novartis position peaked at $6.46M in Q2 2021.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.